for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

H. Lundbeck A/S

LUN.CO

Latest Trade

257.40DKK

Change

-2.10(-0.81%)

Volume

838,102

Today's Range

255.20

 - 

259.80

52 Week Range

169.10

 - 

308.50

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
259.50
Open
259.00
Volume
838,102
3M AVG Volume
11.52
Today's High
259.80
Today's Low
255.20
52 Week High
308.50
52 Week Low
169.10
Shares Out (MIL)
198.70
Market Cap (MIL)
51,260.75
Forward P/E
33.41
Dividend (Yield %)
1.59

Next Event

H Lundbeck A/S at Jefferies Healthcare Conference (Virtual)

Latest Developments

More

Lundbeck: Jacob Tolstrup Sells 5,000 Shares In Co

Lundbeck expects impact on sales in Q2, Q3 from diminishing stockpiles - CFO

H Lundbeck Q1 Reported EBIT At DKK 338 Mln, Below Expectations

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About H. Lundbeck A/S

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimer’s disease, Azilect for the treatment of Parkinson’s disease, Xenazine for the treatment of Huntington’s disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Industry

Biotechnology & Drugs

Contact Info

Ottiliavej 9

2500

Denmark

+45.null.36301311

https://www.lundbeck.com/

Executive Leadership

Lars Soeren Rasmussen

Independent Chairman of the Board

Deborah L. Dunsire

President, Chief Executive Officer

Lene Skole-Soerensen

Deputy Chairman of the Board

Anders Goetzsche

Chief Financial Officer, Executive Vice President

Elise Hauge

Executive Vice President, People & Communication

Key Stats

2.81 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2017

17.2K

2018

18.1K

2019

17.0K

2020(E)

17.9K
EPS (DKK)

2017

12.040

2018

19.660

2019

13.420

2020(E)

7.705
Price To Earnings (TTM)
26.64
Price To Sales (TTM)
2.95
Price To Book (MRQ)
3.63
Price To Cash Flow (TTM)
13.06
Total Debt To Equity (MRQ)
77.33
LT Debt To Equity (MRQ)
76.79
Return on Investment (TTM)
9.34
Return on Equity (TTM)
6.79

Latest News

Latest News

BRIEF-Lundbeck: Jacob Tolstrup Sells 5,000 Shares In Co

* JACOB TOLSTRUP SELLS 5,000 SHARES IN CO WITH PRICE DKK 242.24 PER SHARE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Lundbeck boosted by stockpiling, launches key drug remotely

Danish drugmaker Lundbeck <LUN.CO> beat first-quarter sales expectations on Tuesday as distributors and patients stocked up on medicines amid lockdowns to contain the coronavirus pandemic.

BRIEF-Lundbeck expects impact on sales in Q2, Q3 from diminishing stockpiles - CFO

* CFO SAYS SALES WILL PROBABLY BE AFFECTED BY DIMINISHING DRUG STOCKS IN SECOND AND THIRD QUARTER

Lundbeck beats first-quarter sales expectations, keeps outlook

Danish drugmaker Lundbeck beat first-quarter sales expectations on Tuesday, helped by strong sales from key drugs which benefitted from stock-piling and longer-lasting prescriptions due to the coronavirus pandemic, it said in a statement.

BRIEF-H Lundbeck Q1 Reported EBIT At DKK 338 Mln, Below Expectations

* STRONG MOMENTUM ACROSS ALL STRATEGIC BRANDS WITH 35% GROWTH IN Q1 2020, FINANCIAL GUIDANCE MAINTAINED

BRIEF-Lundbeck Reports Headline Results From Phase Iia Ambled Study Of Foliglurax In Parkinson's Disease

* LUNDBECK REPORTS HEADLINE RESULTS FROM PHASE IIA AMBLED STUDY OF FOLIGLURAX IN PARKINSON'S DISEASE

BRIEF-Lundbeck Gets Grant From Michael J. Fox Foundation For Parkinson's Disease Research

* LUNDBECK RECEIVES GRANT FROM THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S DISEASE RESEARCH Source text for Eikon: Further company coverage: (Gdansk Newsroom)

FDA approves Lundbeck's migraine prevention therapy

The U.S. Food and Drug Administration approved Lundbeck A/S' migraine prevention therapy, which the Danish drugmaker acquired through its near $2 billion deal for Alder BioPharmaceuticals in 2019, the company said on Friday.

BRIEF-U.S. FDA Approves Lundbeck's Vyepti

* FDA APPROVES LUNDBECK'S VYEPTI[™] (EPTINEZUMAB-JJMR) - THE FIRST AND ONLY INTRAVENOUS PREVENTIVE TREATMENT FOR MIGRAINE

U.S. FDA approves Lundbeck's migraine prevention therapy

The U.S. Food and Drug Administration approved Lundbeck A/S' migraine prevention therapy, which the Danish drugmaker acquired through its near $2 billion deal for Alder BioPharmaceuticals in 2019, the company said on Friday.

UPDATE 1-Drugmaker Lundbeck beats Q4 sales expectations

* Expects return to annual growth in 2020 (Adds detail on outlook, dividend, background)

Drugmaker Lundbeck beats Q4 sales expectations, eyes return to growth in 2020

Danish drugmaker Lundbeck posted fourth quarter sales slightly above expectations on Thursday, helped by a stronger performance from key drugs, and said it expected to return to sales growth in 2020.

Lundbeck hikes profit outlook, eyes return to growth in 2020

Danish drugmaker Lundbeck <LUN.CO> raised its outlook for full-year sales and profit on Tuesday following better-than-expected third quarter sales of key drugs and said it expected to return to growth next year, driving its shares over 5% up.

Danish drugmaker Lundbeck ups profit outlook on improved sales

Danish drugmaker Lundbeck raised its outlook for full-year sales and profit after announcing better-than-expected third quarter sales on Tuesday.

Lundbeck buys Alder for $2 billion, eyes 'blockbuster' migraine therapy

Denmark's Lundbeck <LUN.CO> has agreed to buy Alder BioPharmaceuticals <ALDR.O> in a deal valued at almost $2 billion, hoping to reap profits from a potential blockbuster migraine drug.

Lundbeck to buy migraine treatment developer Alder BioPharmaceuticals

Danish pharmaceutical company Lundbeck will acquire Alder BioPharmaceuticals in a deal valued at almost $2 billion, the company said in a statement on Monday.

Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.

UPDATE 1-Danish drugmaker Lundbeck lowers dividend range to fuel growth

* Posts quarterly operating profit below analyst expectations (Adds detail, background, more quotes and share price)

Drugmaker Lundbeck lowers dividend range to fuel growth

Danish drugmaker Lundbeck said on Tuesday it will lower dividends to shareholders as it seeks to invest more to make up for declining sales of older drugs.

UPDATE 1-Lundbeck shares slide as Danish drugmaker's new drugs disappoint

Shares in Lundbeck fell 5 percent on Wednesday after third-quarter sales of the Danish drugmaker's new drugs disappointed and it had to rely on its old line up to prop up revenues.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up